BRCA1 gene expression was significantly downregulated in methylated tumor samples as compared to non-methylated tumors and normal tissues, which suggested that promoter hypermethylation of the BRCA1 gene could serve as a viable biomarker for prostate cancer [18]. This evidence concerns the gene BRCA1 and prostate cancer.